Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) axis have revolutionized advanced non-small cell lung cancer (NSCLC) treatment.
• However, their clinical efficacy is notably restricted in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC.
• Biomarkers effective in EGFR-wild type NSCLC, such as PD-L1 expression and tumor mutation burden, lack predictive power in EGFR-mutated tumors, indicating distinct tumor microenvironment characteristics.

Purpose of the Study:

• To review and summarize existing clinical evidence on ICI efficacy in EGFR-mutated NSCLC.
• To characterize the cancer immunogram features of EGFR-mutated NSCLC, illustrating cancer-immune system interactions.
• To identify potential EGFR-mutated subpopulations that could respond to ICI therapy and propose future treatment strategies.

Main Methods:

• Comprehensive literature review of clinical trials investigating ICIs in EGFR-mutated NSCLC.
• Analysis and depiction of cancer immunogram features, encompassing tumor foreignness, immune effector sensitivity, metabolism, immune status, cellular infiltration, and molecular factors.
• Discussion of potential patient subgroups and future combination immunotherapy approaches.

Main Results:

• Clinical evidence indicates limited response rates of current ICIs in the general EGFR-mutated NSCLC population.
• The cancer immunogram reveals unique immune microenvironment characteristics in EGFR-mutated NSCLC compared to EGFR-wild type.
• Specific subpopulations within EGFR-mutated NSCLC may exhibit differential responses to ICI therapy.

Conclusions:

• EGFR mutations confer unique tumor microenvironment properties that limit the efficacy of standard ICI therapy.
• Further research into cancer immunogram features can identify patient subgroups likely to benefit from ICIs.
• Novel combination immunotherapy strategies are crucial for maximizing ICI benefits in EGFR-mutated NSCLC.